Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has been assigned an average rating of "Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $22.60.
Several research firms recently issued reports on BNTC. Oppenheimer started coverage on shares of Benitec Biopharma in a research report on Wednesday. They issued an "outperform" rating and a $35.00 price target for the company. Leerink Partners started coverage on Benitec Biopharma in a research report on Monday, July 22nd. They set an "outperform" rating and a $13.00 target price for the company. Leerink Partnrs upgraded Benitec Biopharma to a "strong-buy" rating in a research report on Monday, July 22nd. Guggenheim began coverage on Benitec Biopharma in a report on Thursday, September 12th. They set a "buy" rating and a $17.00 price objective for the company. Finally, JMP Securities boosted their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a "market outperform" rating in a research note on Monday.
Read Our Latest Research Report on Benitec Biopharma
Institutional Investors Weigh In On Benitec Biopharma
Institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new stake in shares of Benitec Biopharma during the 2nd quarter valued at $5,881,000. Janus Henderson Group PLC grew its stake in shares of Benitec Biopharma by 35.5% during the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company's stock worth $1,266,000 after purchasing an additional 64,092 shares during the period. Simplify Asset Management Inc. bought a new stake in Benitec Biopharma in the second quarter valued at about $358,000. Finally, GAMMA Investing LLC lifted its stake in Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company's stock valued at $38,000 after buying an additional 1,884 shares during the period. 52.19% of the stock is owned by institutional investors.
Benitec Biopharma Stock Performance
Shares of BNTC stock remained flat at $9.81 during mid-day trading on Wednesday. 34,532 shares of the stock were exchanged, compared to its average volume of 46,717. The firm's fifty day moving average is $9.11 and its 200-day moving average is $8.32. The company has a market capitalization of $91.90 million, a P/E ratio of -5.14 and a beta of 0.90. Benitec Biopharma has a 52 week low of $2.69 and a 52 week high of $12.89.
About Benitec Biopharma
(
Get Free ReportBenitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Stories
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
